Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
I imagine it would be considered highly unethical to tell potential patients that the trial was open to recruitment when it wasn't.
Also they have formally told the markets that the trial is recruiting - I expect it would be against some law to make false statements to the market.
i stand by my theory that Intensive Care capacity will be a big factor in the trial sites coming live. The Liverpool site may be keen and have patients ready, but until Liverpool University Hospital Trust (or whichever hospital is nearest) agrees to preserve an ITU bed then I doubt patient enrolment or dosing can start.
Edinburgh (which is recruiting) has significantly increased their ITU capacity in response to covid and currently has low number of covid patients in ITU across Scotland.
Being purely speculative...
The Clatterbridge Cancer Centre is a specialist hospital for cancer care. It does not (as far as i know) have an intensive care unit. As a novel treatment, I believe protocol dictates that a patient needs a preserved bed in an ITU before they can receive a dose. I wonder if it is this that is holding up the trial? If limited beds are available due to covid, priority on those limited beds could go to the trial needs of the acute hospital, rather than for the cancer hospital over the road.
I am honestly both surprised and disappointed, that having initially set the expectation that covidity recruitment would be no problem and Moditop would be recruiting around new year, only to dash both of those against the rocks at the interim, that the company doesn't feel a significant obligation to keep the shareholders more up to date than they ordinarily would. The fact that they haven't even given us a single update since then is staggering to me.
I never thought I would be tempted to divest, but the temptation is creeping up.
I think it's fair to say none of us on this board are "trolls"... some are just beyond frustrated with this company. A shareholder is well within their rights to question the board and their approach, without being written off as "trolls or troublemakers". SB has a fiduciary duty to the shareholders - whether they are big or small.
I certainly knew when I investd in CICC that it was high risk - but that doesn't give the company the right to be opaque and to treat small private investors with contempt or derision. We deserve to know what has happened to our investment. We invested, and invested long in the CICC portfolio, based on a series of claims and statements from SB. Apart from the temporary listing of CIC Gold, then nothing has delivered a return and we have been locked in for years. Even with the temporary listing of the CIC Gold shell company, it still failed to deliver on any of its prospectus. The only way CIC Gold could be considered a success is to whoever trousered all of the money that shareholders put into it.
They say the clearest indicator of the future is to look at the past.. in that context, it would be reasonable to think that Innomedtech will (at best) list as a shell company for a matter of months, before delisting.
That's just my point.. if they are the same class as shares, you can't pay out some and not others.
Do those 22 that have been contacted hold a different class of share to the rest of us? Otherwise I am fairly sure it would not be legal to selectively pay dividends
am i reading this correctly?? Cic are now selectively choosing which share holders to issue dividends to?
I suppose the two other factors to consider here are:
1) The size of a batch of DNA Vaccine versus MRNA vaccine. My understanding is DNA is easier to manufacture but would be interested if someone has the numbers
2) The global capacity to manufacture MRNA vs DNA now. I expect MRNA capacity has gone through the roof, comparatively speaking, in the last 12 months.
According to latest figures, there are 438 people across the whole of the UK in ICU with Covid. That's about half what it was at the beginning of the month, and 1/10th of its peak at the beginning of 2021.
We were relatively recently told by Lindy that the Modi-1 trial was anticipated to start before the end of 2021. Then we were told this was delayed due to lack of available ICU beds - or at least the concern that Omicorn may drive up ICU bed utilisation. Given that hasn't proven to be the reality, the question has to be - what's the hold up now?